These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16840706)

  • 21. An intriguing new lead on Huntington's disease.
    Barinaga M
    Science; 1996 Mar; 271(5253):1233-4. PubMed ID: 8638101
    [No Abstract]   [Full Text] [Related]  

  • 22. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
    Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
    Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of pathological and nonpathological human exon 1 huntingtin.
    Singer D; Zauner T; Genz M; Hoffmann R; Zuchner T
    J Pept Sci; 2010 Jul; 16(7):358-63. PubMed ID: 20552561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Huntington's disease: seeing the pathogenic process through a genetic lens.
    Gusella JF; MacDonald ME
    Trends Biochem Sci; 2006 Sep; 31(9):533-40. PubMed ID: 16829072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
    Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
    Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo models for Huntington disease: lessons for the polyglutamine expansion disorders.
    Hayden MR
    Pathol Biol (Paris); 1998 Nov; 46(9):695-6. PubMed ID: 9885820
    [No Abstract]   [Full Text] [Related]  

  • 28. Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?
    Rangone H; Humbert S; Saudou F
    Pathol Biol (Paris); 2004 Jul; 52(6):338-42. PubMed ID: 15261377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are there multiple pathways in the pathogenesis of Huntington's disease?
    Aronin N; Kim M; Laforet G; DiFiglia M
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):995-1003. PubMed ID: 10434298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Huntingtin and its role in neuronal degeneration.
    Li SH; Li XJ
    Neuroscientist; 2004 Oct; 10(5):467-75. PubMed ID: 15359012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity.
    Kaytor MD; Wilkinson KD; Warren ST
    J Neurochem; 2004 May; 89(4):962-73. PubMed ID: 15140195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypothesis: Huntingtin may function in membrane association and vesicular trafficking.
    Truant R; Atwal R; Burtnik A
    Biochem Cell Biol; 2006 Dec; 84(6):912-7. PubMed ID: 17215878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
    Kahlem P; Green H; Djian P
    Mol Cell; 1998 Mar; 1(4):595-601. PubMed ID: 9660943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
    Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S
    Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Astrocytes in Huntington's chorea: accomplice or guilty of the neuronal death?].
    Liévens JC; Birman S
    Med Sci (Paris); 2007 Oct; 23(10):845-9. PubMed ID: 17937893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Huntingtin processing in pathogenesis of Huntington disease.
    Qin ZH; Gu ZL
    Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does tissue transglutaminase play a role in Huntington's disease?
    Lesort M; Chun W; Tucholski J; Johnson GV
    Neurochem Int; 2002 Jan; 40(1):37-52. PubMed ID: 11738471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington's disease.
    Lathrop RH; Casale M; Tobias DJ; Marsh JL; Thompson LM
    Proc Int Conf Intell Syst Mol Biol; 1998; 6():105-14. PubMed ID: 9783215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease.
    Joshi AS; Thakur AK
    J Pept Sci; 2014 Aug; 20(8):630-9. PubMed ID: 24788406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.